Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3Thoracic 1

Conditions

Carcinoma, Renal Cell 3Small Cell Lung Carcinoma 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × OTHER × vorolanib × Clear all
NCT07386158 2026-02-04

Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC

Sun Yat-sen University

Phase 2 Recruiting
21 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT04373369 2025-11-03

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Washington University School of Medicine

Phase 2 Terminated
11 enrolled 10 charts
Thoracic

Small Cell Lung Carcinoma

NCT07047001 2025-07-09

Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Active not recruiting
60 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT06523049 2024-07-26

Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy

West China Hospital

Phase 2 Not yet recruiting
67 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡